FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	e Responses)														
1. Name and Address of Reporting Person* Curd John G				2. Issuer Name and Ticker or Trading Symbol THRESHOLD PHARMACEUTICALS INC [THLD]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director Officer (give title below) President and CMO					
C/O PUDECUAL D DILL DI CLOCUPICALI C				3. Date of Earliest Transaction (Month/Day/Year) 03/11/2011									Presi	dent and CM)	
(Street) REDWOOD CITY, CA 94063				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
(City)	(State)	(Zip)			Table	I - Non-D	erivative	Securition	es Acqui	ired, D	Disposed	of, or Benef	ficially Owner	d	
1.Title of Se (Instr. 3)				2A. Deemed Execution Date, if		(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		d	Ownership of Form:	7. Nature of Indirect Beneficial	
				(Month/	Day/Year)	Co	ode V	Amoun	(A) or (D)	Price	(Instr.	. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	
Common	Stock		03/11/2011			P	(1)	11,904	1 A	\$ 2.1 (3)				D		
Reminder: F	Report on a se	eparate line for each	class of securities b	eneficiall	y owned d	irectly	Pers in thi	ons who s form :		equired	d to re	spond (ion contain form displa		1474 (9-02)
Reminder: F	Report on a se	enarate line for each	class of securities b	eneficiall	v owned d	irectly	or indirect	lv.								
1. Title of	2. Conversion	3. Transaction	Table II - 3A. Deemed Execution Date, if	Derivati (e.g., put 4. Transac Code	ve Securit is, calls, w 5. Nu of Deriv	ies Acarrant	Pers in thi	ons who s form a rently v sposed o converti	are not realid OMI f, or Benealible secure and	equired B contre eficially ities) 7. Title of Une	Owned and Aderlyin	espond umber. d Amount	8. Price of		ays	11. Natur of Indired Beneficia
1. Title of Derivative Security	2. Conversion or Exercise	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., put 4. Transac Code	ve Securit is, calls, w 5. Nu of Deriv	ies Acarrant mber ative ities ired sed	Persin thing a current quired, Dites, options, 6. Date Expiration	ons who s form a rently v sposed o converti	are not realid OMI f, or Benealible secure and	equired B contre eficially ities) 7. Title of Une	Owned and Aderlyin ities	espond umber. d Amount	8. Price of Derivative Security	9. Number of Derivative Securities	f 10. Owners Form of Derivati Security Direct (or Indire	11. Natur of Indirec Beneficia Ownersh (Instr. 4)
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivati (e.g., put 4. Transac Code	ve Securities, calls, we state of the control of Deriv Securition (A) of Deriv (A) of Disposor of (D) (Instr	ies Acarrant mber ative ities ired sed	Persin thing a current quired, Dites, options, 6. Date Expiration	ons who s form a rently v sposed o convertice convertice and Date ay/Year)	are not r alid OMI f, or Bene ible secur e and	equired B contre eficially ities) 7. Title of Une	Owned e and Aderlyinities 3 and	espond umber. d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transactions	f 10. Owners Form of Derivati Security Direct (or Indirects)	11. Natur of Indirec Beneficia Ownersh (Instr. 4)

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Curd John G C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BLVD. SUITE 500 REDWOOD CITY, CA 94063			President and CMO			

Signatures

John G. Curd by Joel Fernandes, Attorney-In-Fact	03/15/2011
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Acquired from Issuer pursuant to a Prospectus Supplement dated March 11, 2011.
- (2) Includes 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on August 13, 2010, and 3,000 shares acquired under the Issuer's Employee Stock Purchase Plan on February 12, 2011 at a per share price of \$1.003.
- (3) Purchase price per unit. Each unit consists of 1 common share and a warrant to purchase 0.4 of a share of common stock at an exercise price of \$2.46 per share.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.